中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

515 records (took 0.036 seconds)

    APHERESIS SYSTEM INCORPORATING ALTERNATIVE SITE FOR ANTICOAGULANT ADDITION
    142.
    发明申请
    APHERESIS SYSTEM INCORPORATING ALTERNATIVE SITE FOR ANTICOAGULANT ADDITION 审中-公开
    加入反刍动物添加剂的替代品系统的APHERESIS系统

    公开(公告)号：WO1994019031A1

    公开(公告)日：1994-09-01

    申请号：PCT/US1994001630

    申请日：1994-02-17

    Applicant: BAXTER INTERNATIONAL INC.

    Inventor： BAXTER INTERNATIONAL INC. ,  SCHOENDORFER, Donald, W.

    IPC: A61M01/36

    CPC classification number: A61M1/3672 ,  A61M1/30 ,  A61M1/303 ,  A61M1/3673

    Abstract: An extracorporeal blood processing method and system (14) wherein blood is extracted from a mammalian subject through a blood withdrawal tube (16) having a blood pump (18), such as a peristaltic pump, positioned thereon. A "distal segment" of the blood withdrawal tube (16) extends from the mammalian subject to the inlet side of withdrawal pump (18). A "proximal segment" of the blood withdrawal tube (16) extends from the outlet side of the blood pump (18) to an extracorporeal blood processing apparatus (14). An anticoagulant feed tube (24) is connected to the "proximal segment" of the blood withdrawal tube (16) such that a flow of anticoagulant solution may be combined with blood exiting the outlet of said blood pump (18) and passing through the "proximal segment" of said blood withdrawal tubing (16).

    Abstract translation: 一种体外血液处理方法和系统（14），其中通过具有定位在其上的具有诸如蠕动泵的血液泵（18）的抽血管（16）从哺乳动物受试者中提取血液。 抽血管（16）的“远端”部分从哺乳动物受试者延伸到抽取泵（18）的入口侧。 抽血管（16）的“近端”部分从血液泵（18）的出口侧延伸到体外血液处理装置（14）。 抗凝剂供给管（24）连接到抽血管（16）的“近端段”，使得抗凝血剂溶液流可以与离开血泵（18）的出口的血液结合并通过“ 所述抽血管（16）的近端段“。

    RAPID METHOD FOR DETERMINING CRITICAL VAPOR PRESSURE
    143.
    发明申请
    RAPID METHOD FOR DETERMINING CRITICAL VAPOR PRESSURE 审中-公开
    用于确定关键蒸汽压力的快速方法

    公开(公告)号：WO1994011727A1

    公开(公告)日：1994-05-26

    申请号：PCT/US1993010515

    申请日：1993-11-03

    Applicant: BAXTER INTERNATIONAL INC.

    Inventor： BAXTER INTERNATIONAL INC. ,  WOOD, Ray, W. ,  HANSEN, Lee, D. ,  CRAWFORD, John, W.

    IPC: G01N25/48

    CPC classification number: G01N25/56 ,  G01N25/4846

    Abstract: A method of determining the critical vapor pressure of a hygroscopic material, such as a drug. A drug sample is placed in a substantially isothermal environment. A vapor, such as water vapor, at a given pressure is then placed in the ambient air over the drug. The rate of heat production from this sample at the given water vapor pressure, or the humidity of the air above the sample, is then measured. The water vapor pressure over the drug is gradually increased. Simultaneously, the rate of increase in heat production from the drug sample, or the rate of change of the relative humidity of the air above the drug sample, is measured. A marked increase in the rate of heat production generated by the drug, or a marked change in the relative humidity of the air over the sample, signals the attainment of the critical water vapor pressure.

    Abstract translation: 确定吸湿材料如药物的临界蒸气压的方法。 将药物样品置于基本上等温的环境中。 然后在给定压力下的蒸气（例如水蒸气）被放置在药物上的环境空气中。 然后测量在给定水蒸气压下该样品的热量产生率或样品上方空气的湿度。 药物上的水蒸汽压力逐渐增加。 同时，测定药物样品的产生热量的增加率，或药物样品上方的空气相对湿度的变化率。 药物产生的热量产生明显增加，或样品上空气的相对湿度发生明显变化，表明达到临界水汽压力。

    CANNULA FOR USE IN DRUG DELIVERY SYSTEMS
    144.
    发明申请
    CANNULA FOR USE IN DRUG DELIVERY SYSTEMS 审中-公开
    用于药物输送系统的肛门

    公开(公告)号：WO1994003118A1

    公开(公告)日：1994-02-17

    申请号：PCT/US1993006661

    申请日：1993-07-14

    Applicant: BAXTER INTERNATIONAL INC.

    Inventor： BAXTER INTERNATIONAL INC. ,  BANCSI, Joseph, A. ,  ELLER, Charles ,  FOWLES, Thomas, A. ,  GORMAN, Brian, J. ,  HEBRON, Terrence, J. ,  JERSILD, Charles ,  JESS, Donald, A. ,  WONG, Joseph, C., T. ,  WOOD, Ray, W.

    IPC: A61B19/00

    CPC classification number: A61M5/1409 ,  Y10S604/905

    Abstract: The present invention provides an improved cannula (22) that can be used to reconstitute powdered drugs in a drug delivery system. Furthermore, the present invention provides a cannula (22) and drug delivery system incorporating same. To this end, the present invention provides a cannula structure for use in a reconstitution of a powdered drug comprising a cannula (22) having a first end (26) and a second end (28), and defining a channel in an interior thereof between the first and second ends (26, 28). The first end (26) is closed and includes a member (27) for piercing a septum (42). The cannula (22) includes at least two slots (50a, 50b) providing fluid communication between the channel and an exterior of the cannula (22). The slots (50a, 50b) are located in juxtaposition to the first end (26) and have a width, as measured along a length of the cannula (22), that is less than a length, as measured around the cannula (22). The slots (50a, 50b) also have a minimum projected area equal to or greater than the cross-sectional area of the channel.

    Abstract translation: 本发明提供了可用于在药物递送系统中重建粉末状药物的改进的插管（22）。 此外，本发明提供一种套管（22）和并入其的药物递送系统。 为此，本发明提供了一种用于重构粉末药物的插管结构，其包括具有第一端（26）和第二端（28）的插管（22），并且在其内部限定通道 第一和第二端（26,28）。 第一端（26）是关闭的并且包括用于刺穿隔膜（42）的构件（27）。 插管（22）包括至少两个槽（50a，50b），其在通道和套管（22）的外部之间提供流体连通。 狭槽（50a，50b）位于第一端（26）上并且沿着套管（22）的长度测量的宽度小于在套管（22）周围测量的长度， 。 狭槽（50a，50b）还具有等于或大于通道的横截面面积的最小投影面积。

    ADDITIVES FOR POLYMER COMPOSITIONS
    146.
    发明申请
    ADDITIVES FOR POLYMER COMPOSITIONS 审中-公开
    聚合物组合物的添加剂

    公开(公告)号：WO1993024563A1

    公开(公告)日：1993-12-09

    申请号：PCT/US1993004567

    申请日：1993-05-12

    Applicant: BAXTER INTERNATIONAL INC.

    Inventor： BAXTER INTERNATIONAL INC. ,  BUAN, Lillian ,  LAURIN, Dean

    IPC: C08K05/00

    CPC classification number: C08K5/1515 ,  C08K5/0008 ,  C08K5/098 ,  C08K5/56 ,  C08L27/06

    Abstract: The present invention provides an additive system for vinyl chloride polymer formulations to improve both the processing of the formulations and the functional characteristics of medical products made from the formulations. The additive system surprisingly exceeds previously known systems with respect to the melt fabrication and heat stability of the polymer formulations and the desired product characteristics of the products manufactured from such materials. Preferably, the additive system of the present invention comprises optimal amounts of the combination of a zinc salt primary stabilizer with an epoxide secondary stabilizer and a polyethylene external lubricant. Other processing aids and performance additives such as bases, antioxidants and internal lubricants, may be included. The additive system can be utilized with either plasticized or non-plasticized vinyl chloride polymer formulations.

    Abstract translation: 本发明提供用于氯乙烯聚合物制剂的添加剂体系，以改进制剂的加工和由制剂制备的医疗产品的功能特征。 相对于聚合物制剂的熔体制造和热稳定性以及由这些材料制造的产品的期望的产品特性，该添加剂系统令人惊奇地超过了先前已知的体系。 优选地，本发明的添加剂体系包含最佳量的锌盐一级稳定剂与环氧化物二级稳定剂和聚乙烯外部润滑剂的组合。 可以包括其它加工助剂和性能添加剂，例如碱，抗氧化剂和内部润滑剂。 添加剂体系可以与塑化或非塑化氯乙烯聚合物配方一起使用。

    VASCULAR IMPLANT SYSTEM
    148.
    发明申请
    VASCULAR IMPLANT SYSTEM 审中-公开
    血管植入系统

    公开(公告)号：WO1993020757A2

    公开(公告)日：1993-10-28

    申请号：PCT/US1993003517

    申请日：1993-04-14

    Applicant: BAXTER INTERNATIONAL INC.

    Inventor： BAXTER INTERNATIONAL INC. ,  QUIJANO, R., C. ,  NASHEF, Aws

    IPC: A61B17/11

    CPC classification number: A61F2/2475 ,  A61B17/11 ,  A61F2/07 ,  A61F2/2418

    Abstract: Exovascular (10) and endovascular (100) stent devices and associated support/restrictor assemblies (30, 104, 106) for use in conjunction with prosthetic vascular grafts (12), including venous valve grafts made from preserved bioprosthetic venous valves (119). Also disclosed are methods for preparing vascular grafts (12) such as venous valve grafts using the devices and assemblies of the present invention.

    Abstract translation: 血管内（10）和血管内（100）支架装置和用于与假体血管移植物（12）结合使用的相关支撑/限制器组件（30,104,106），包括由保存的生物假肢静脉瓣（119）制成的静脉瓣移植物。 还公开了使用本发明的装置和组件来制备血管移植物（12）的方法，例如静脉瓣移植物。

    SYSTEMS AND METHODS FOR CELLS IMPLANTS
    149.
    发明申请
    SYSTEMS AND METHODS FOR CELLS IMPLANTS 审中-公开
    细胞植入物的系统和方法

    公开(公告)号：WO1993019700A1

    公开(公告)日：1993-10-14

    申请号：PCT/US1993002665

    申请日：1993-03-25

    Applicant: BAXTER INTERNATIONAL INC.

    Inventor： BAXTER INTERNATIONAL INC. ,  BRAUKER, James, H. ,  HILL, Ronald, S. ,  MARTINSON, Laura, A. ,  BOGGS, Daniel, R. ,  JOHNSON, Robert, C.

    IPC: A61F02/02

    CPC classification number: A61K9/0024 ,  A61B5/14532 ,  A61F2/022 ,  A61L27/38 ,  A61L27/56 ,  A61L29/005 ,  A61L29/146

    Abstract: Implant assemblies (10) and methodologies provide immuno-protection for implanted allografts, xenografts, and isografts. The assemblies and methodologies establish an improved boundary (34) between the host and the implanted cells. The boundary (34) has a pore size, an ultimate strength, and a metabolic transit value that assures the survival of the cells during the critical ischemic period and afterward. The boundary (34) allows the fabrication and clinical use of implant assemblies (10) and methodologies that can carry enough cells to be of therapeutic value to the host, yet occupy a relatively small, compact area within the host.

    Abstract translation: 植入组件（10）和方法为植入的同种异体移植物，异种移植物和同种移植物提供免疫保护。 组件和方法在主机和植入的细胞之间建立改进的边界（34）。 边界（34）具有孔隙尺寸，极限强度和代谢转运值，可确保临界缺血期及以后细胞的存活。 边界（34）允许植入组件（10）的制造和临床使用以及可以携带足够的细胞对宿主具有治疗价值的植入物组件（10）和方法，而占据主机内相对较小，紧凑的区域。

    IN VITRO-DERIVED HUMAN NEUTROPHIL PRECURSOR CELLS
    150.
    发明申请
    IN VITRO-DERIVED HUMAN NEUTROPHIL PRECURSOR CELLS 审中-公开
    在体外衍生的人中性粒细胞前体细胞

    公开(公告)号：WO1993018648A1

    公开(公告)日：1993-09-30

    申请号：PCT/US1993002860

    申请日：1993-03-23

    Applicant: BAXTER INTERNATIONAL INC.

    Inventor： BAXTER INTERNATIONAL INC. ,  BENDER, James, G. ,  MAPLES, Phillip, B. ,  SMITH, Stephen ,  UNVERZAGT, Kristen, L. ,  VAN EPPS, Dennis, E.

    IPC: A01N01/00

    CPC classification number: A61K35/15 ,  A61K48/00 ,  A61K2039/5156 ,  C12N5/0642 ,  C12N2500/44 ,  C12N2501/22 ,  C12N2501/23 ,  C12N2501/39

    Abstract: A composition comprising human neutrophil precursor cells, wherein the cellular component is comprised of at least about 16 % human myeloblasts and promyelocytes, which have been derived from neutrophil progenitor cells obtained from peripheral blood, bone marrow or cord blood, and less than about 5 % colony forming units (CFU) of at least about 50 cells is provided. An alternative composition comprising human neutrophil precursor cells, wherein the cellular component is comprised of at least about 16 % CD15+CD11b- cells and less than about 5 % colony forming units (CFU) of at least about 50 cells also is provided, wherein at least about 60 % of the CD15+CD11b- cells are myeloblasts and promyelocytes.

    Abstract translation: 一种包含人嗜中性粒细胞前体细胞的组合物，其中所述细胞组分由至少约16％的人成髓细胞和前髓细胞组成，所述成骨细胞源自从外周血，骨髓或脐带血获得的嗜中性粒细胞祖细胞，并且小于约5％ 提供至少约50个细胞的集落形成单位（CFU）。 一种包含人嗜中性粒细胞前体细胞的替代组合物，其中所述细胞组分由至少约16％的CD15 + CD11b-细胞组成，并且还提供至少约50个细胞的小于约5％的集落形成单位（CFU），其中在 至少约60％的CD15 + CD11b细胞是成髓细胞和前髓细胞。

Patent Agency Ranking